More from the ASCO Oncology conference: Array BioPharma (ARRY) says its MEK162 selective inhibitor shows promising clinical activity in Phase ll trial in patients with NRAS mutated melanoma. Shares +2.5% AH.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Jan 15, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Jun 13, 2014)
at CNBC.com (Jul 1, 2013)
at CNBC.com (Jun 19, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs